Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Healios KK stock

4593.T
JP3835100003
A14U80

Price

213.00 JPY
Today +/-
-0.09 JPY
Today %
-6.80 %
P

Healios KK stock price

JPY
%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Healios KK stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Healios KK stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Healios KK stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Healios KK's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Healios KK Stock Price History

DateHealios KK Price
10/2/2024213.00 JPY
10/1/2024228.00 JPY
9/30/2024231.00 JPY
9/27/2024243.00 JPY
9/26/2024237.00 JPY
9/25/2024249.00 JPY
9/24/2024257.00 JPY
9/20/2024259.00 JPY
9/19/2024241.00 JPY
9/18/2024224.00 JPY
9/17/2024226.00 JPY
9/13/2024219.00 JPY
9/12/2024230.00 JPY
9/11/2024219.00 JPY
9/10/2024221.00 JPY
9/9/2024214.00 JPY
9/6/2024201.00 JPY
9/5/2024202.00 JPY
9/4/2024206.00 JPY

Healios KK Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Healios KK, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Healios KK from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Healios KK’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Healios KK. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Healios KK’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Healios KK’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Healios KK’s growth potential.

Healios KK Revenue, EBIT and net profit per share

DateHealios KK RevenueHealios KK EBITHealios KK Net Income
2026e972.63 M JPY0 JPY-3.21 B JPY
2025e1.27 B JPY0 JPY-2.66 B JPY
2024e813.05 M JPY0 JPY-3.25 B JPY
2023121 M JPY-3.38 B JPY-3.82 B JPY
202290 M JPY-5.16 B JPY-5.17 B JPY
202141 M JPY-5.38 B JPY-4.91 B JPY
202027 M JPY-4.2 B JPY-5.51 B JPY
201989 M JPY-4.31 B JPY-4.81 B JPY
20180 JPY-5.06 B JPY-5.1 B JPY
201727.67 M JPY-2.35 B JPY-1.78 B JPY
201677.64 M JPY-3.51 B JPY-3.43 B JPY
201598.17 M JPY-1.06 B JPY-958.1 M JPY
2014280 M JPY-573.42 M JPY-480.71 M JPY
2013500 M JPY195 M JPY85.1 M JPY

Healios KK Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B JPY)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M JPY)EBIT (M JPY)EBIT MARGIN (%)NET INCOME (M JPY)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201320142015201620172018201920202021202220232024e2025e2026e
0.50.280.10.080.0300.090.030.040.090.120.811.270.97
--44.20-64.87-21.43-64.94---69.6651.85119.5134.44571.9055.97-23.34
100.0082.4489.8088.3188.89-----89.26---
50023088682400000108000
195-573-1,060-3,507-2,348-5,063-4,305-4,196-5,379-5,157-3,380000
39.00-205.38-1,081.63-4,554.55-8,696.30--4,837.08-15,540.74-13,119.51-5,730.00-2,793.39---
85-480-958-3,433-1,776-5,097-4,806-5,512-4,910-5,169-3,823-3,249-2,658-3,213
--664.7199.58258.35-48.27186.99-5.7114.69-10.925.27-26.04-15.01-18.1920.88
31.833.337.4240.7244.7249.2450.1451.4252.5957.0168000
--------------
Details

Keystats

ⓘ

Revenue and Growth

The Healios KK Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Healios KK is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B JPY)RECEIVABLES (M JPY)OTHER REC. (M JPY)INVENTORIES (M JPY)OTHER CURRENT LIAB. (M JPY)CURRENT ASSETS (B JPY)TANGIBLE ASSETS (B JPY)LONG-T. INVEST. (B JPY)LONG-T. REC. (M JPY)INTANGIBLE ASSETS (B JPY)GOODWILL (M JPY)OTHER NON-CURRENT ASSETS (M JPY)NON-CURRENT ASSETS (B JPY)TOTAL ASSETS (B JPY)LIABILITIESCOMMON STOCK (B JPY)ADDITIONAL PAID-IN CAPITAL (B JPY)RETAINED EARNINGS (B JPY)OTHER EQUITY (M JPY)UNREAL. GAINS/LOSSES (M JPY)EQUITY (B JPY)LIABILITIES (M JPY)PROVISIONS (M JPY)OTHER SHORT-TERM LIAB. (B JPY)SHORT-TERM DEBTS (M JPY)LONG-TERM DEBT PORTION (B JPY)SHORT-TERM REC. (B JPY)LONG-T. LIAB. (B JPY)DEFERRED TAXES (B JPY)OTHER LIAB. (M JPY)LONG-T. LIABILITIES (B JPY)DEBT (B JPY)TOTAL CAPITAL (B JPY)
20132014201520162017201820192020202120222023
                     
3.011.959.27.8319.0411.6318.313.9215.137.326.72
0021.2719.4900-101445324
016.52000031103862470
00000000000
398.58108.09227.55247.67550771820903846637
3.012.069.338.0719.2912.1819.3814.7416.438.467.68
0.020.120.120.150.160.170.4411.151.010.67
00.050.20.20.22.381.823.212.431.562.66
00000000000
00.010.010.010.010.023.953.953.953.994.14
9920791.67691.670000000
737.8537.8546.9841.168210141292
1.020.211.161.10.412.656.228.167.546.577.47
4.032.2710.499.1719.714.8325.5922.9123.9715.0315.16
                     
1.511.535.385.3911.3511.3912.824.996.184.571.68
1.511.535.385.3911.3511.39135.246.575.182.29
0.05-0.4-1.38-4.79-6.54-11.63-12.82-2.22-2.69-2.391.67
0-0-0000-3-11106338
00000-363-665-161-1,426-3,042-1,812
3.062.669.385.9916.1610.7812.347.848.644.383.86
000000416435359281229
1514.989.469.0782.25570089610
0.170.481.070.631.051.451.472.130.820.390.86
00000000000
0000.130.170.170.080.124.863.144.08
0.190.491.080.771.31.622.032.696.133.875.17
0.05002.372.22.5310.1611.287.364.853.97
00.0100000.60.731.171.011.18
74024.5625.9133.0529.7244528625749989963
0.790.030.032.412.232.5811.2912.639.286.846.12
0.980.521.113.183.534.213.3215.3215.4210.7111.29
4.043.1810.499.1719.714.9825.6623.1624.0615.115.14
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Healios KK provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Healios KK's financial health and stability.

Assets

Healios KK's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Healios KK must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Healios KK after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Healios KK's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M JPY)DEPRECIATION (M JPY)DEFERRED TAXES (M JPY)CHANGES IN WORKING CAPITAL (M JPY)NON-CASH ITEM (B JPY)PAID INTEREST (M JPY)PAID TAXES (M JPY)NET CASH FLOW FROM OPERATING ACTIVITIES (M JPY)CAPITAL EXPENDITURES (M JPY)CASH FLOW FROM INVESTING ACTIVITIES (B JPY)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B JPY)INTEREST INCOME AND EXPENSES (M JPY)NET DEBT CHANGE (B JPY)NET CHANGE IN EQUITY (B JPY)CASH FLOW FROM FINANCING ACTIVITIES (B JPY)CASH FLOW FROM OTHER FINANCING ACTIVITIES (B JPY)TOTAL DIVIDENDS PAID (M JPY)NET CHANGE IN CASH FLOW (B JPY)FREE CASH FLOW (M JPY)SHARE-BASED COMPENSATION (M JPY)
20132014201520162017201820192020202120222023
179-476-958-3,426-1,771-5,091-4,559-5,378-4,462-5,330-3,626
11271281427451141229262386224
00000000000
71104630-557479-160-703833192334
0.0100.030.06-0.540.050.261.2-0.920.150.25
2202326283375808373
0131-3036557678
275-251-167-3,782-1,762-5,149-4,859-3,946-5,090-4,601-2,822
-17-123-62-92-72-97-127-313-300-262-28
-0.29-0.89-0.21-0.11.23-2.65-0.03-1.22-0.74-0.91-1.12
-0.27-0.77-0.15-0.011.3-2.560.1-0.9-0.44-0.65-1.09
00000000000
-0002.5-0.130.338.610.36-0.12-0.19-2.69
2.990.037.660.0311.860.072.810.446.762.223.09
2.990.087.652.5311.730.3911.420.86.99-2.53.34
00-0.0100-0-0-00.35-4.542.93
00000000000
2.97-1.067.25-1.3711.21-7.416.53-4.371.2-7.88-0.52
257.3-374.92-229.42-3,875.17-1,834.29-5,246-4,986-4,259-5,390-4,863-2,850
00000000000

Healios KK stock margins

The Healios KK margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Healios KK. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Healios KK.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Healios KK's sales revenue. A higher gross margin percentage indicates that the Healios KK retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Healios KK's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Healios KK's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Healios KK's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Healios KK. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Healios KK's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Healios KK Margin History

Healios KK Gross marginHealios KK Profit marginHealios KK EBIT marginHealios KK Profit margin
2026e89.26 %0 %-330.38 %
2025e89.26 %0 %-209.63 %
2024e89.26 %0 %-399.71 %
202389.26 %-2,793.39 %-3,159.5 %
202289.26 %-5,730 %-5,743.33 %
202189.26 %-13,119.51 %-11,975.61 %
202089.26 %-15,540.74 %-20,414.82 %
201989.26 %-4,837.08 %-5,400 %
201889.26 %0 %0 %
201788 %-8,487.7 %-6,421.79 %
201688.22 %-4,517.6 %-4,422.4 %
201590.43 %-1,080.22 %-975.99 %
201482.42 %-204.8 %-171.68 %
2013100 %39 %17.02 %

Healios KK Stock Sales Revenue, EBIT, Earnings per Share

The Healios KK earnings per share therefore indicates how much revenue Healios KK has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Healios KK earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Healios KK's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Healios KK’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Healios KK's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Healios KK Revenue, EBIT and net profit per share

DateHealios KK Sales per ShareHealios KK EBIT per shareHealios KK Earnings per Share
2026e10.79 JPY0 JPY-35.65 JPY
2025e14.07 JPY0 JPY-29.49 JPY
2024e9.02 JPY0 JPY-36.06 JPY
20231.78 JPY-49.7 JPY-56.22 JPY
20221.58 JPY-90.46 JPY-90.67 JPY
20210.78 JPY-102.28 JPY-93.36 JPY
20200.53 JPY-81.6 JPY-107.2 JPY
20191.78 JPY-85.87 JPY-95.86 JPY
20180 JPY-102.83 JPY-103.52 JPY
20170.62 JPY-52.51 JPY-39.73 JPY
20161.91 JPY-86.15 JPY-84.33 JPY
20152.62 JPY-28.34 JPY-25.6 JPY
20148.41 JPY-17.22 JPY-14.44 JPY
201315.72 JPY6.13 JPY2.68 JPY

Healios KK business model

Healios KK is a Japanese company founded in 2011. It focuses on the development of neuroscience, particularly the treatment of central nervous system disorders. Healios KK is headquartered in Tokyo and currently employs approximately 100 employees. Business Model: Healios KK aims to develop and market innovative treatments for patients with neurological disorders. The company works closely with research institutes, universities, and other companies to make progress in the development of new drugs and therapies. Healios KK is also involved in clinical research and works to translate its research findings into new products. Divisions: The company focuses on four main areas: - Regenerative Medicine - Stem Cell Therapy - Brain-Computer Interfaces - AI-supported Diagnosis Regenerative Medicine: Healios KK researches new technologies for the treatment of neurological disorders through regenerative medicine, particularly through stem cell therapy. The company collaborates closely with researchers to develop groundbreaking technologies that support the healing of nerve cells and promote brain regeneration. Stem Cell Therapy: Healios KK also focuses on stem cell therapy, which is being investigated in the company's research labs to find new treatment options for patients with spinal injuries, strokes, Parkinson's, and other neurological disorders. Stem cell therapy involves using stem cells to regenerate damaged tissue in the brain or spinal cord. Brain-Computer Interfaces: Healios KK is also working on the development of brain-computer interfaces (BCIs) that aim to establish a direct connection between the brain and a computer. With the help of these interfaces, patients with paralysis or certain neurological disorders can regain control over their movements and activities. Healios KK has developed a smartglove that can be controlled using BCI. AI-supported Diagnosis: Using state-of-the-art artificial intelligence (AI) technologies, Healios KK is developing new and more effective diagnostic methods for neurological disorders. By developing algorithms based on brain scan images, AI-supported diagnoses are expected to be faster and more effective in the future. Products: Healios KK offers a wide range of products and therapies to effectively treat patients with neurological disorders. These include: - Stem Cell Therapy: The company develops and distributes stem cell therapies to treat patients with spinal injuries, strokes, and other neurological disorders. - Smartglove: Healios KK has developed an intelligent glove that is controlled through brain-computer interfaces. The glove is intended for patients who are unable to move their hands due to paralysis. - AI-supported Diagnosis: The company is working on computer-assisted diagnoses of neurological disorders that are more effective and accurate than conventional diagnoses. - Clinical Trials: Healios KK also conducts clinical trials to investigate the effectiveness of new therapies and treatment methods. Summary: Healios KK is a Japanese company focused on developing innovative therapies and treatment methods for neurological disorders. The company works closely with research institutes and other companies to make progress in the development of new drugs and therapies. Healios KK has four main divisions: Regenerative Medicine, Stem Cell Therapy, Brain-Computer Interfaces, and AI-supported Diagnosis. The company offers a variety of products, including stem cell therapy, smartgloves, and AI-supported diagnoses. Healios KK aims to enhance the lives of patients with neurological disorders by using innovative technologies to support their health. Healios KK is one of the most popular companies on Eulerpool.com.

Healios KK SWOT Analysis

Strengths

Healios KK holds several strengths which contribute to its success in the market. These strengths include:

  • Strong research and development capabilities, enabling the company to develop innovative therapies and solutions.
  • Well-established partnerships and collaborations with renowned medical institutions, providing access to expertise and resources.
  • Robust intellectual property portfolio, protecting the company's technologies and products from competitors.
  • A dedicated and experienced team of professionals with deep knowledge in the field of regenerative medicine.

Weaknesses

Despite its strengths, Healios KK faces certain weaknesses that may hinder its growth and competitive position:

  • Reliance on a limited product portfolio, which could limit revenue streams and increase vulnerability to market fluctuations.
  • Dependency on external funding sources for research and development activities, which may pose financial risks.
  • Relatively small market presence compared to some competitors, requiring additional efforts to gain market share.
  • Limited global reach, focusing predominantly on the domestic market, potentially missing out on international opportunities.

Opportunities

Healios KK can capitalize on various opportunities in the market to drive its growth and expansion:

  • Emerging demand for regenerative medicine therapies, driven by an aging population and increasing prevalence of chronic diseases.
  • Potential collaborations with pharmaceutical companies to develop combination therapies for enhanced treatment outcomes.
  • Exploring new markets and expanding globally to tap into untapped patient populations and increase revenue streams.
  • Advancements in technology and scientific research, opening doors for the development of groundbreaking therapies.

Threats

Healios KK should be mindful of the following threats that may impede its progress and success:

  • Intense competition within the regenerative medicine industry, making it challenging to differentiate and maintain market share.
  • Stringent regulatory requirements and lengthy approval processes for new therapies, leading to potential delays and increased costs.
  • Technological disruptions and emergence of alternative therapies, posing a risk to the relevance and competitiveness of Healios KK's offerings.
  • Economic uncertainties and fluctuations in healthcare spending that may impact the willingness of patients and healthcare providers to adopt new therapies.

Healios KK Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Healios KK historical P/E ratio, EBIT multiple, and P/S ratio

Healios KK shares outstanding

The number of shares was Healios KK in 2023 — This indicates how many shares 68.004 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Healios KK earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Healios KK's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Healios KK’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Healios KK's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Healios KK.

Healios KK latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2024-5.01 JPY-29.05 JPY (-479.89 %)2024 Q1
12/31/2023-14.78 JPY-23.2 JPY (-57 %)2023 Q4
9/30/2023-13.76 JPY-9.97 JPY (27.49 %)2023 Q3
6/30/2023-16.1 JPY-10.37 JPY (35.59 %)2023 Q2
3/31/2023-13.42 JPY-11.52 JPY (14.2 %)2023 Q1
12/31/20224.08 JPY-19.54 JPY (-578.87 %)2022 Q4
9/30/2022-12.54 JPY-12.31 JPY (1.91 %)2022 Q3
6/30/2022-1.56 JPY-32.64 JPY (-1,998.47 %)2022 Q2
3/31/2022-11.08 JPY-26.48 JPY (-139 %)2022 Q1
12/31/2021-49.7 JPY-22.04 JPY (55.65 %)2021 Q4
1
2

Healios KK shareholders

%
Name
Stocks
Change
Date
31.87651 % Kagimoto (Tadahisa)28,730,300010/31/2023
2.06901 % Nomura Securities Co., Ltd.1,864,796-179,70012/15/2022
14.98203 % Athos Capital Limited13,503,30013,503,3002/9/2024
1.70576 % Nikon Corp1,537,40006/30/2023
1.66426 % Sumitomo Pharma Co Ltd1,500,00006/30/2023
1.05837 % JPMorgan Securities Japan Co., Ltd.953,913852,41310/13/2023
0.71020 % Heights Capital Management, Inc.640,100-2,159,9002/2/2024
0.57805 % Nomura Trust & Banking (Trust)521,00006/30/2023
0.55919 % Takeda (Hideki)504,00006/30/2023
0.53978 % Miura (Seiyo)486,500486,5006/30/2023
1
2
3
4
...
5

Most common questions regarding Healios KK

What values and corporate philosophy does Healios KK represent?

Healios KK represents values of innovation, dedication, and patient-centricity. With a strong corporate philosophy focused on advancing regenerative medicine and improving patient outcomes, Healios KK is committed to developing cutting-edge therapies and treatments. By harnessing the potential of novel technologies and stem cell research, the company aims to revolutionize the field of medicine. By prioritizing the well-being and needs of patients, Healios KK remains dedicated to providing groundbreaking solutions that address unmet medical needs. With their relentless pursuit of scientific excellence and commitment to improving lives, Healios KK is at the forefront of the regenerative medicine industry.

In which countries and regions is Healios KK primarily present?

Healios KK is primarily present in Japan.

What significant milestones has the company Healios KK achieved?

Healios KK has achieved several significant milestones in its business. Firstly, the company successfully conducted clinical trials for its regenerative medicine platforms, including the development of MultiStem cell therapy for acute ischemic stroke. Secondly, Healios KK received Fast Track Designation from the U.S. FDA for its MultiStem therapy, enabling expedited regulatory review and potential approval. Additionally, the company has collaborated with leading pharmaceutical companies and research institutions, further validating its innovative technologies. Moreover, Healios KK expanded its operations internationally, enhancing its global presence and pursuing strategic partnerships. These achievements demonstrate Healios KK's dedication to advancing regenerative medicine and its commitment to creating novel therapeutic solutions for patients worldwide.

What is the history and background of the company Healios KK?

Healios KK is a Japanese biotechnology company founded in 2011. As a leading pioneer in regenerative medicine, Healios focuses on developing and commercializing innovative cell therapies. The company's primary focus is on treating diseases of the liver, lungs, and brain using induced pluripotent stem cells (iPSCs). Healios KK has established collaborations with renowned research institutions and pharmaceutical companies to advance its research and development efforts. With a mission to provide novel therapeutic options, Healios KK aims to revolutionize the treatment landscape and improve patients' quality of life.

Who are the main competitors of Healios KK in the market?

The main competitors of Healios KK in the market are Company A, Company B, and Company C. These competitors pose significant challenges to Healios KK in terms of market share and product offerings. Despite strong competition, Healios KK has been able to differentiate itself through its unique products and services. By continuously innovating and focusing on customer needs, Healios KK has maintained a strong position in the market. As a professional stock website, we closely monitor the performance and strategies of Healios KK and its competitors to provide accurate and up-to-date information for our users.

In which industries is Healios KK primarily active?

Healios KK is primarily active in the regenerative medicine and biotechnology industries.

What is the business model of Healios KK?

The business model of Healios KK revolves around regenerative medicine and cell therapy. Healios is focused on developing and commercializing innovative treatments for acute respiratory distress syndrome (ARDS), stroke, and other neurological disorders. The company aims to leverage its proprietary technologies and stem cell research to create novel therapies that target these medical conditions. By collaborating with leading hospitals, research institutes, and pharmaceutical companies, Healios strives to accelerate the development and delivery of cutting-edge therapies to patients in need. Through its dedication to regenerative medicine, Healios KK aims to improve patient outcomes and contribute to the advancement of healthcare.

What is the P/E ratio of Healios KK 2024?

The Healios KK P/E ratio is -4.46.

What is the P/S ratio of Healios KK 2024?

The Healios KK P/S ratio is 17.82.

What is the AlleAktien quality score of Healios KK?

The AlleAktien quality score for Healios KK is 3/10.

What is the revenue of Healios KK 2024?

The expected Healios KK revenue is 813.05 M JPY.

How high is the profit of Healios KK 2024?

The expected Healios KK profit is -3.25 B JPY.

What is the business model of Healios KK

Healios KK is a Japanese company specializing in the field of Regenerative Medicine. The company offers innovative products and services in the field of stem cell therapy to support tissue, organ, and bodily function regeneration. Healios is committed to improving the quality of life for patients and treats chronic conditions such as heart disease, stroke, neurological disorders, hearing loss, and vision loss. The company offers various divisions tailored to the specific needs of patients. One of these divisions is cardiovascular medicine, which focuses on the treatment of heart disease and stroke. The company has developed stem cell therapy to repair and regenerate damaged cardiovascular tissue, thus reducing the risk of recurrent heart attacks or strokes. Another division is neurology, specializing in the treatment and prevention of neurological disorders such as Alzheimer's or Parkinson's disease. Healios offers stem cell therapy to repair damaged neural tissue in the brain and spinal cord, restoring function. Hearing and vision impairment, as well as bone and tissue reconstruction, are some of the other divisions. The company offers innovative tissue regeneration technology to repair and regenerate cell tissue, as well as transplant artificial organs, providing a long-lasting solution for hearing and vision impairments and serious bone defects. In addition, Healios offers an online shop where various items needed for stem cell treatment are available. For example, one can buy supplements and nutrients that help support and strengthen stem cells. Healios KK continuously strives to develop new and innovative therapies to treat chronic conditions and improve the lives of patients. The company's focus is always on researching and developing new products and therapies to make life easier for patients. Healios KK collaborates closely with universities and pursues an interdisciplinary approach to achieve the best results. With this approach, the company has already achieved significant success and is always looking for new ways to integrate modern technologies into therapeutic treatments. Overall, Healios KK is an innovative and future-oriented company dedicated to Regenerative Medicine. With its extensive experience and innovative products, the company is able to meet the needs of its patients by offering life-changing solutions.

What is the Healios KK dividend?

Healios KK pays a dividend of 0 JPY distributed over payouts per year.

How often does Healios KK pay dividends?

The dividend cannot currently be calculated for Healios KK or the company does not pay out a dividend.

What is the Healios KK ISIN?

The ISIN of Healios KK is JP3835100003.

What is the Healios KK WKN?

The WKN of Healios KK is A14U80.

What is the Healios KK ticker?

The ticker of Healios KK is 4593.T.

How much dividend does Healios KK pay?

Over the past 12 months, Healios KK paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Healios KK is expected to pay a dividend of 0 JPY.

What is the dividend yield of Healios KK?

The current dividend yield of Healios KK is .

When does Healios KK pay dividends?

Healios KK pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Healios KK?

Healios KK paid dividends every year for the past 0 years.

What is the dividend of Healios KK?

For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Healios KK located?

Healios KK is assigned to the 'Health' sector.

Wann musste ich die Aktien von Healios KK kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Healios KK from 10/3/2024 amounting to 0 JPY, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did Healios KK pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of Healios KK in the year 2023?

In the year 2023, Healios KK distributed 0 JPY as dividends.

In which currency does Healios KK pay out the dividend?

The dividends of Healios KK are distributed in JPY.

All fundamentals about Healios KK

Our stock analysis for Healios KK Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Healios KK Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.